1. Home
  2. GTY vs AUPH Comparison

GTY vs AUPH Comparison

Compare GTY & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Getty Realty Corporation

GTY

Getty Realty Corporation

HOLD

Current Price

$33.07

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.98

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTY
AUPH
Founded
1955
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
GTY
AUPH
Price
$33.07
$15.98
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$32.60
$17.25
AVG Volume (30 Days)
334.1K
1.2M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
5.92%
N/A
EPS Growth
8.00
5075.00
EPS
0.43
0.25
Revenue
$221,727,000.00
$283,055,000.00
Revenue This Year
$9.39
$17.54
Revenue Next Year
$7.83
$15.74
P/E Ratio
$76.70
$63.36
Revenue Growth
9.02
20.38
52 Week Low
$25.39
$7.29
52 Week High
$34.75
$16.88

Technical Indicators

Market Signals
Indicator
GTY
AUPH
Relative Strength Index (RSI) 54.82 54.94
Support Level $32.44 $14.53
Resistance Level $33.99 $16.29
Average True Range (ATR) 0.66 0.54
MACD -0.02 0.07
Stochastic Oscillator 72.84 60.52

Price Performance

Historical Comparison
GTY
AUPH

About GTY Getty Realty Corporation

Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: